Article Versions Notes

Chaigneau L, Lapp E, Jai T, Dobi E, Martin B, Curtit E, Nerich V. Real-World Evidence of Long-Term Disease Control in HER2-Positive Metastatic Breast Cancer Patients Treated with a First-Line Combination of Trastuzumab and/or Pertuzumab Plus Chemotherapy. Cancers. 2025; 17(21):3532. https://doi.org/10.3390/cancers17213532

Chaigneau, Loïc, Eva Lapp, Taha Jai, Erion Dobi, Berenger Martin, Elsa Curtit, and Virginie Nerich. 2025. "Real-World Evidence of Long-Term Disease Control in HER2-Positive Metastatic Breast Cancer Patients Treated with a First-Line Combination of Trastuzumab and/or Pertuzumab Plus Chemotherapy" Cancers 17, no. 21: 3532. https://doi.org/10.3390/cancers17213532

Chaigneau, L., Lapp, E., Jai, T., Dobi, E., Martin, B., Curtit, E., & Nerich, V. (2025). Real-World Evidence of Long-Term Disease Control in HER2-Positive Metastatic Breast Cancer Patients Treated with a First-Line Combination of Trastuzumab and/or Pertuzumab Plus Chemotherapy. Cancers, 17(21), 3532. https://doi.org/10.3390/cancers17213532